Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the close of its Series E financing round at a total of around $123 million, surpassing its initial target amid strong investor interest.

ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients

ClearNote Health announced initiation of patient enrollment for a new study that aims to advance early detection of pancreatic cancer in individuals newly diagnosed with type 2 diabetes.

Astoriom Appoints Brittany Jackson as CFO

Key appointment to lead the company’s financial strategy and support continued global growth in sample stability and biorepository storage solutions

Microsoft Xbox Co-Founder, Cameron Ferroni, Joins PhenoTips as CTO

PhenoTips, a leading provider of precision medicine software, announces the appointment of Microsoft Xbox co-founder Cameron Ferroni as Fractional CTO to scale the Genomic Health Record platform and bolster leadership.

CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development

Extends capabilities of industry-leading PhysioMimix DILI assay for comparative studies between animal species and human Generates deeper insights into inter-species differences to de-risk development pipelines and minimize animal testing

Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care

Echosens and Boehringer Ingelheim have expanded their long-standing partnership to accelerate progress in MASH diagnosis and care.

Majority of Diagnostic Laboratory Leaders Bet Big on Digital Pathology and AI

Survey of 360 senior professionals finds modernization is key to overcoming longstanding industry challenges

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach

Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025. Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced the greatest mean improvement in lung function, as measured by forced vital capacity (FVC), with a mean change of +98.4 mL, compared to a mean decline of -20.3 mL in the placebo group. Exploratory biomarkers analyses further validated the biological mechanism of TNIK, the novel target identified through a generative AI approach, supporting Rentosertib’s potential anti-fibrotic and anti-inflammatory effects. Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized medicine, and unlocking unprecedented opportunities to accelerate drug discovery and delivery. Despite growing adoption, only a few AI-discovered or AI-designed drug candidates have advanced to clinical trials, and even fewer have demonstrated clinical proof-of-concept.

TeleTracking and Palantir Partner to Transform Healthcare Operations with AI-Powered Insights

Inizio Evoke Announces Medical Leadership Evolution: Matthew Hoelzle Named Chief Medical Officer

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics announces positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company’s nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers, and the company’s next phase of clinical development.

Annual Cotiviti Client Conference Focuses on AI, Interoperability and Reducing Healthcare Costs

Industry Leading RBQM Event Returns for 2025

CluePoints, the premier sponsor of RBQMLive and provider of leading statistical and AI-driven software solutions, has announced the full agenda and expert speaker line up for the 4th annual, award-winning event, RBQMLive.

Tjoapack continues to expand its global infrastructure with strategic investments in injectable packaging and cold chain capabilities

BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement

BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement

Linus Health Study Champions Person-Centered Brain Health Assessments

Linus Health Study Champions Person-Centered Brain Health Assessments

Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research

Orbitrap Astral Zoom and Orbitrap Excedion Pro deliver increased speed and sensitivity to set a new performance benchmark for high-resolution, accurate mass spectrometry

1upHealth Launches Prior Authorization Solution and Technology Partnerships to Support CMS Electronic Prior Authorization Mandate for Health Plans

Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director

The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics

Latest Nature Communications Study: AI-Enabled Development of Next-Generation ENPP1 Inhibitors for Innate Immune Modulation by Insilico Medicine

Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI in drug discovery. Unlike direct STING agonists, ISM5939 precisely modulates the STING pathway within tumor tissues by targeting ENPP1, thereby restoring local immune activation and enhancing anti-tumor immune responses. For the first time, ENPP1 inhibitors have been shown to overcome dual resistance to immune checkpoint inhibitors and chemotherapy, offering a new therapeutic hope for patients with refractory tumors. Since the start of 2025, this marks Insilico Medicine’s third AI-driven drug discovery study published in a Nature sub-journal. Immune checkpoint inhibitors have transformed cancer treatment, providing clinical benefits for a wide range of malignancies. However, only ~10-35% of patients on these treatments achieve a meaningful and durable response, underscoring the urgent need for innovative therapeutic strategies.